Form 144 Axsome Therapeutics, Filed by: Pizzie Nick
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities
February 18, 2025 1:13 PM ESTTruist Securities analyst Joon Lee raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "4Q24. No surprises to results preannounced in January. More importantly, Ph3 study of solriamfetol in... More
